



1646

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1242)

In the Application of:

Ward et al.

Serial No.: 09/936,964

Filing Date: March 15, 2000

For: Anti-p53 Antibodies

Examiner: TBA

Group Art Unit: 1646

Confirmation No.: 4441

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:

- a) Supplementary Partial European Search Report;
- b) Information Disclosure Statement;
- c) PTO Form 1449 and 8 references cited therein; and
- d) return receipt postcard.


2. With respect to fees:

- a) A fee is not required at this time.
- b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on July 3, 2003.

Date: July 3, 2003

Respectfully submitted,


Michael S. Greenfield
Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
(312)913-0001

RECEIVED
JUL 10 2003
TECH CENTER 1600/2900



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1242)

In the Application of:

Ward et al.

Serial No.: 09/936,964

Filing Date: March 15, 2000

For: Anti-p53 Antibodies

Examiner: TBA

Group Art Unit: 1646

Confirmation No.: 4441

PH10

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449.

For Information Disclosure Statements submitted after receipt of a foreign Search Report, a copy of such Search Report is attached.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

FOREIGN PATENT DOCUMENTS

1. PCT Patent No. WO 98/56416, published 17 December 1998.

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on July 3, 2003.

Date: July 3, 2003


Michael S. Greenfield


2. Australian Patent No. WO 98/18825, published 7 May 1998.

OTHER DOCUMENTS

3. Ruiz et al. "Idiotypic Immunization Induces Immunity to Mutated p53 and Tumor Rejection" Nature Medicine, Vol. 4, No. 6, June 1998.
4. Angelopoulou et al. "Humoral Immune Response Against p53 Protein in Patients with Colorectal Carcinoma" Int. J. Cancer: 70, 46-51 (1997).
5. Kovacs et al. "Concise Communications" Arthritis & Rheumatism, Vol. 40, No. 5, May 1997, pp. 980-985.
6. Yip et al. "Evaluation of Different Lymphoid Tissue Sources for the Construction of Human Immunoglobulin Gene Libraries" Immunotechnology 3 (1997) 195-203.
7. Leitha et al. "Is Early Sestamibi Imaging in Head and Neck Cancer Affected by MDR Status, p53 Expression, or Cell Proliferation?" Nuclear Medicine & Biology, Vol. 25, pp. 539-541, 1998.
8. Reisfeld and Gillies "Recombinant Antibody Fusion Proteins for Cancer Immunotherapy" XP-001030927

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Date: July 3, 2003

By: 
Michael S. Greenfield
Reg. No. 37,142

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

00-1242

Serial No.

09/936,964



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

Applicant:

Ward et al.

Filing Date:

March 15, 2000

Group:

1646

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	WO 98/56416	17 December 1998	PCT	39	395	✓	
	2.	WO 98/18825	7 May 1998	Australia	16	18	✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

		3.	Ruiz et al. "Idiotypic Immunization Induces Immunity to Mutated p53 and Tumor Rejection" Nature Medicine, Vol. 4, No. 6, June 1998.
		4.	Angelopoulou et al. "Humoral Immune Response Against p53 Protein in Patients with Colorectal Carcinoma" Int. J. Cancer: 70, 46-51 (1997).
		5.	Kovacs et al. "Concise Communications" Arthritis & Rheumatism, Vol. 40, No. 5, May 1997, pp. 980-985.
		6.	Yip et al. "Evaluation of Different Lymphoid Tissue Sources for the Construction of Human Immunoglobulin Gene Libraries" Immunotechnology 3 (1997) 195-203.
		7.	Leitha et al. "Is Early Sestamibi Imaging in Head and Neck Cancer Affected by MDR Status, p53 Expression, or Cell Proliferation?" Nuclear Medicine & Biology, Vol. 25, pp. 539-541, 1998.

		8.	Reisfeld and Gillies "Recombinant Antibody Fusion Proteins for Cancer Immunotherapy" XP-001030927
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

